This bill matters to voters because it directly impacts access to medication abortion, a common method of ending pregnancy in the United States. If this bill becomes law, it would make it harder for people to get mifepristone by reinstating rules that the FDA had previously relaxed, such as potentially requiring in-person visits to a healthcare provider for prescription and restricting dispensing to a limited number of certified providers, rather than certified pharmacies. This could mean more travel, higher costs, and less privacy for individuals seeking this medication, especially for those in rural areas or with limited resources.

Conversely, if this bill does not become law, the current, less restrictive rules for mifepristone that the FDA put in place in January 2023 would remain in effect. This would maintain the current level of access for patients and providers, allowing for prescriptions by a wider range of healthcare providers and dispensing through certified pharmacies, including by mail. The outcome of this bill could therefore significantly alter the landscape of reproductive healthcare access.